ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年11月30日 17時30分
Source:
Eisai
エーザイ、11名の先端医療機関の専門家および8名のエーザイ研究者による「レカネマブ」の早期アルツハイマー病に対する臨床第III相Clarity AD検証試験結果の論文がthe New England Journal of Medicineに掲載
東京, 2022年11月30日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とバイオジェン・インク (Nasdaq: BIIB、本社:米国マサチューセッツ州ケンブリッジ、CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブ(開発品コード:BAN2401)について、脳内アミロイド病理が確認されたアルツハイマー病(AD)による軽度認知障害(Mild Cognitive Impairment:MCI)および軽度AD(これらを総称して早期ADと定義)を対象とした大規模なグローバル臨床第III相Clarity AD検証試験の結果が世界的に最も権威のある医学雑誌の一つである査読学術専門誌the New England Journal of Medicineに掲載されたことをお知らせします。
今回のClarity AD試験結果の迅速な論文化は、エーザイのヒューマンヘルスケア理念に基づく、信頼性、透明性に対する強いコミットメントの証です。引き続き、エーザイとバイオジェンは、レカネマブに関するデータと情報の開示に努め、本剤が承認された際には、必要とする当事者様、ご家族に一刻も早く本剤をお届けできるよう全力を尽くしてまいります。
レカネマブについて、エーザイは、開発および薬事申請をグローバルに主導し、エーザイの最終意思決定権のもとで、エーザイとバイオジェンが共同商業化・共同販促を行います。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202284.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 31, 2025 11:00 JST
Fujitsu and Macquarie University partner to help address critical shortage of machine learning engineers
Mar 31, 2025 09:28 JST
HKTDC Export Confidence Index 1Q25
Mar 29, 2025 19:36 JST
Hua Medicine Announces 2024 Annual Results
Mar 28, 2025 22:51 JST
Mitsubishi Corporation, ADM Sign Non-Binding MOU, Form Strategic Alliance
Mar 28, 2025 16:29 JST
Everbright Grand China Assets Recorded Revenue of RMB 45.9 Million in 2024
Mar 28, 2025 14:27 JST
NEC and COEDO Brewery develop the second edition of "The taste of life created by brewers and AI -- Agentic AI x Craft Beer"
Mar 28, 2025 13:08 JST
Akanetsu Installs Heat Source Facilities Utilizing Green Hydrogen, the First Such Initiative by a District Heating and Cooling Company in Central Tokyo
Mar 27, 2025 14:00 JST
Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Hartsfield-Jackson Atlanta International Airport
Mar 27, 2025 11:53 JST
China Travel International's Revenue Reached HK$4,627 Million in 2024, Profit Attributable to Operation Grew 8% Year-on-Year
Mar 27, 2025 10:44 JST
Hitachi to Install a New Digital Maturity Assessment Method to Accelerate DX in Global Manufacturing Operations
Mar 26, 2025 17:13 JST
TGR Launches Partially Upgraded Supra RZ Grade and Special-edition Supra "A90 Final Edition" in Japan
Mar 26, 2025 15:25 JST
NEC provides 25G tunable SFP extended reach optical transceiver
Mar 26, 2025 14:41 JST
Start of Joint Study on Integrated Power and Data Center Business in Ohgishima area in Keihin District
Mar 26, 2025 14:31 JST
TANAKA Announces Executive Appointments
Mar 26, 2025 03:00 JST
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 17:28 JST
NEC receives order for walkthrough gates leveraging face recognition technology to facilitate more seamless airport arrival and departure procedures
Mar 25, 2025 17:14 JST
NTT, DOCOMO and NEC Demonstrate World's Fastest 140 Gbps Bidirectional Wireless Transmission in 80 GHz Band
Mar 25, 2025 16:40 JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 25, 2025 12:21 JST
DENSO the First Company Headquartered in Japan to Acquire EcoPass Certification from Catena-X
Mar 24, 2025 18:02 JST
More Latest Release >>
Related Release
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
3/25/2025 5:28:00 PM JST
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
3/25/2025 12:21:00 PM JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
2/14/2025 12:09:00 PM JST
More Press release >>